[{"id":6799,"regimens":[{"id":13742,"duration":{"id":7634,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12627,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13742},{"id":12628,"answer":"In a novel combination with another drug","answer_other":"","regimen":13742}],"created":"2020-12-25T06:36:50.854219Z","updated":"2020-12-25T07:11:55.635833Z","dose":"200 mg","frequency":"BD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6799},{"id":13743,"duration":{"id":7635,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":12629,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13743},{"id":12630,"answer":"In a novel combination with another drug","answer_other":"","regimen":13743}],"created":"2020-12-25T06:36:50.861868Z","updated":"2020-12-25T07:11:55.642103Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6799},{"id":13744,"duration":{"id":7636,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9780,"name":"Piperacillin-Tazobactam","url":"cure-api2.ncats.io/v1/drugs/9780","rxNorm_id":null,"notes":null},"use_drug":[{"id":12631,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13744},{"id":12632,"answer":"In a novel combination with another drug","answer_other":"","regimen":13744}],"created":"2020-12-25T06:36:50.868401Z","updated":"2020-12-25T07:11:55.647634Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6799},{"id":13745,"duration":{"id":7637,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12633,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13745},{"id":12634,"answer":"In a novel combination with another drug","answer_other":"","regimen":13745}],"created":"2020-12-25T06:36:50.874453Z","updated":"2020-12-25T07:11:55.706523Z","dose":null,"frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6799},{"id":13746,"duration":{"id":7638,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10130,"name":"Ribavirin","url":"cure-api2.ncats.io/v1/drugs/10130","rxNorm_id":null,"notes":null},"use_drug":[{"id":12635,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13746},{"id":12636,"answer":"In a novel combination with another drug","answer_other":"","regimen":13746}],"created":"2020-12-25T06:36:50.880845Z","updated":"2020-12-25T07:11:55.658786Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6799},{"id":13747,"duration":{"id":7639,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11275,"name":"Pegylated Interferon","url":"cure-api2.ncats.io/v1/drugs/11275","rxNorm_id":null,"notes":null},"use_drug":[{"id":12637,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13747},{"id":12638,"answer":"In a novel combination with another drug","answer_other":"","regimen":13747}],"created":"2020-12-25T06:36:50.887268Z","updated":"2020-12-25T07:11:55.664410Z","dose":"Single dose","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6799},{"id":13748,"duration":{"id":7640,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":12639,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13748},{"id":12640,"answer":"In a novel combination with another drug","answer_other":"","regimen":13748}],"created":"2020-12-25T06:36:50.893511Z","updated":"2020-12-25T07:11:55.670206Z","dose":"2 doses","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6799},{"id":13749,"duration":{"id":7641,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12641,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13749},{"id":12642,"answer":"In a novel combination with another drug","answer_other":"","regimen":13749}],"created":"2020-12-25T06:36:50.899378Z","updated":"2020-12-25T07:11:55.675605Z","dose":"400 mg, 2 doses","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6799}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8958,"answer":"Clinical assessment","answer_other":"","report":6799},{"id":8959,"answer":"PCR","answer_other":"","report":6799}],"how_diagnosis":[{"id":15368,"answer":"Clinical assessment","answer_other":"","report":6799},{"id":15369,"answer":"Imaging","answer_other":"","report":6799},{"id":15370,"answer":"PCR","answer_other":"","report":6799}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5035,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6799}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":604,"answer":"White","answer_other":""}],"created":"2020-12-25T06:33:55.010716Z","updated":"2020-12-25T07:11:55.628021Z","title":"Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases. Case 3","status":"Approved","anonymous":false,"published":true,"pubmed_id":32632355,"doi":"10.1016/j.rmcr.2020.101139","article_url":"https://pubmed.ncbi.nlm.nih.gov/32632355/","pub_year":2020,"published_authors":"ElSeirafi MM\r\nHasan HM\r\nSridharan K\r\nZamoori A\r\nAlkhawaja S\r\nPasha SAA","article_author_email":"Author email could not be found.","journal":"Respiratory medicine case reports","abstract":"Tocilizumab has been recognized as one of the few existing biologic useful for combating COVID-19 infections especially in critically ill patient. We had experience in treating five critically ill patients with severe lung injury who were COVID-19 positive with tocilizumab. In the present case series, we have attempted to summarize their clinical profile, changes in laboratory biomarkers and outcomes.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"61-70 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Bahrain","country_treated":"Bahrain","began_treatment_year":"2020","hiv":false,"asthma":true,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Obesity","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"Nasopharyngeal swab for COVID-19 was positive and the patient was initiated on oral hydroxychloroquine 200 mg twice daily along with ceftriaxone, piperacillin/tazobactam, aizthromycin, ribavirin, pegylated interferon (received single dose) and plasma therapy (two doses). The patient did not show any signs of improvement but his oxygen requirement increased for maintaining appropriate oxygen saturation. The patient was shifted to ICU and was administered two doses of 400 mg tocilizumab infusion. Patient improved the following day with a negative COVID-19 test results twice on alternate days and the patient was discharge from ICU.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,6675,11339,8342,11275,9780,10130,10776]},{"id":6800,"regimens":[{"id":13750,"duration":{"id":7642,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":12643,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13750},{"id":12644,"answer":"In a novel combination with another drug","answer_other":"","regimen":13750}],"created":"2020-12-25T06:51:51.520817Z","updated":"2020-12-25T07:10:20.916990Z","dose":"200 mg","frequency":"BD","route":"PO","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6800},{"id":13751,"duration":{"id":7643,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":12645,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13751},{"id":12646,"answer":"In a novel combination with another drug","answer_other":"","regimen":13751}],"created":"2020-12-25T06:51:51.530376Z","updated":"2020-12-25T07:10:20.923299Z","dose":"","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6800},{"id":13752,"duration":{"id":7644,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":12647,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13752},{"id":12648,"answer":"In a novel combination with another drug","answer_other":"","regimen":13752}],"created":"2020-12-25T06:51:51.537067Z","updated":"2020-12-25T07:10:20.928794Z","dose":null,"frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6800},{"id":13753,"duration":{"id":7645,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":12649,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13753},{"id":12650,"answer":"In a novel combination with another drug","answer_other":"","regimen":13753}],"created":"2020-12-25T06:51:51.543458Z","updated":"2020-12-25T07:10:20.988848Z","dose":null,"frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6800},{"id":13754,"duration":{"id":7646,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10130,"name":"Ribavirin","url":"cure-api2.ncats.io/v1/drugs/10130","rxNorm_id":null,"notes":null},"use_drug":[{"id":12651,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13754},{"id":12652,"answer":"In a novel combination with another drug","answer_other":"","regimen":13754}],"created":"2020-12-25T06:51:51.549692Z","updated":"2020-12-25T07:10:20.940163Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6800},{"id":13755,"duration":{"id":7647,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11275,"name":"Pegylated Interferon","url":"cure-api2.ncats.io/v1/drugs/11275","rxNorm_id":null,"notes":null},"use_drug":[{"id":12653,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13755},{"id":12654,"answer":"In a novel combination with another drug","answer_other":"","regimen":13755}],"created":"2020-12-25T06:51:51.569732Z","updated":"2020-12-25T07:10:20.945872Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6800},{"id":13756,"duration":{"id":7648,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11339,"name":"Convalescent plasma","url":"cure-api2.ncats.io/v1/drugs/11339","rxNorm_id":null,"notes":null},"use_drug":[{"id":12655,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13756},{"id":12656,"answer":"In a novel combination with another drug","answer_other":"","regimen":13756}],"created":"2020-12-25T06:51:51.575760Z","updated":"2020-12-25T07:10:20.951739Z","dose":"2 doses","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6800},{"id":13757,"duration":{"id":7649,"approximate_duration":null,"dates_unknown":false},"drug":{"id":10776,"name":"Tocilizumab","url":"cure-api2.ncats.io/v1/drugs/10776","rxNorm_id":null,"notes":null},"use_drug":[{"id":12657,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13757},{"id":12658,"answer":"In a novel combination with another drug","answer_other":"","regimen":13757}],"created":"2020-12-25T06:51:51.581880Z","updated":"2020-12-25T07:10:20.957224Z","dose":"400 mg, 2 doses","frequency":"","route":"IV","severity":"ICU/Critical Care","severity_detail":null,"comments":null,"report":6800}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8960,"answer":"Clinical assessment","answer_other":"","report":6800},{"id":8961,"answer":"PCR","answer_other":"","report":6800}],"how_diagnosis":[{"id":15371,"answer":"Clinical assessment","answer_other":"","report":6800},{"id":15372,"answer":"Imaging","answer_other":"","report":6800},{"id":15373,"answer":"PCR","answer_other":"","report":6800}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":5036,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6800}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":605,"answer":"White","answer_other":""}],"created":"2020-12-25T06:49:43.851862Z","updated":"2020-12-25T07:10:20.909151Z","title":"Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases. Case 4","status":"Approved","anonymous":false,"published":true,"pubmed_id":32632355,"doi":"10.1016/j.rmcr.2020.101139","article_url":"https://pubmed.ncbi.nlm.nih.gov/32632355/","pub_year":2020,"published_authors":"ElSeirafi MM\r\nHasan HM\r\nSridharan K\r\nZamoori A\r\nAlkhawaja S\r\nPasha SAA","article_author_email":"Author email could not be found.","journal":"Respiratory medicine case reports","abstract":"Tocilizumab has been recognized as one of the few existing biologic useful for combating COVID-19 infections especially in critically ill patient. We had experience in treating five critically ill patients with severe lung injury who were COVID-19 positive with tocilizumab. In the present case series, we have attempted to summarize their clinical profile, changes in laboratory biomarkers and outcomes.","article_type":"Original","study_type":"Case Report","number_of_patients":5,"article_patient_number":"4","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"31-40 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Bahrain","country_treated":"Bahrain","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"None","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"The patient received oral hydroxychloroquine 200 mg twice daily along with ceftriaxone, lopinavir/ritonavir, aizthromycin, ribavirin, pegylated interferon (received single dose) and plasma therapy (two doses). Patient did not show any signs of improvement. His oxygen requirement continued to increase. Two doses of tocilizumab 400 mg were administered. Following the second dose of tocilizumab, the patient showed marked signs of improvement and four days later he was found to be negative for COVID-19 test and a repeat test after two days was still negative. The patient was discharged from ICU on day 5.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,6675,11339,8342,8783,11275,10130,10776]}]